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Abstract
Background: Amplification of 1q21 is the most frequent genetic alteration in hepatocellular carcinoma (HCC), which was
detected in 58–78% of primary HCC cases by comparative genomic hybridization (CGH). Using chromosome microdissection/
hybrid selection approach we recently isolated a candidate oncogene CHD1L from 1q21 region. Our previous study has
demonstrated that CHD1L had strong oncogenic ability, which could be effectively suppressed by siRNA against CHD1L. The
molecular mechanism of CHD1L in tumorigenesis has been associated with its role in promoting cell proliferation.
Methodology/Principal Findings: To further investigate the in vivo oncogenic role of CHD1L, CHD1L ubiquitous-expression
transgenic mouse model was generated. Spontaneous tumor formations were found in 10/41 (24.4%) transgenic mice,
including 4 HCCs, but not in their 39 wild-type littermates. In addition, alcohol intoxication was used to induce hepatocyte
pathological lesions and results found that overexpression of CHD1L in hepatocytes could promote tumor susceptibility in
CHD1L-transgenic mice. To address the mechanism of CHD1L in promoting cell proliferation, DNA content between CHD1L-
transgenic and wildtype mouse embryo fibroblasts (MEFs) was compared by flow cytometry. Flow cytometry results found
that CHD1L could facilitate DNA synthesis and G1/S transition through the up-regulation of Cyclin A, Cyclin D1, Cyclin E,
CDK2, and CDK4, and down-regulation of Rb, p27
Kip1, and p53.
Conclusion/Significance: Taken together, our data strongly support that CHD1L is a novel oncogene and plays an important
role in HCC pathogenesis
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
solid tumors in the world affecting one million individuals annually
[1]. The prognosis of HCC is very poor and the overall 5-year
survival rate is less than 5%, mainly because of the late diagnosis
[2]. Although different etiologic factors such as hepatitis B virus
and hepatitis C virus infection, aflatoxin exposure, and alcoholic
cirrhosis have been associated with the development of HCC, the
genetic events involved in the pathogenesis of HCC are still
unclear [3]. One of the most frequently detected genetic
alterations in HCC is the amplification of the long arm of
chromosome 1, which has been detected in 58–78% HCC patients
by comparative genomic hybridization [4–7]. A minimal amplified
region at 1q has been narrowed down to 1q21 [7,8], suggesting the
existence of an oncogene at 1q21 which plays an important role in
HCC pathogenesis.
Recently, we used microdissected DNA from 1q21 to select region-
specific transcripts from an HCC case with 1q21 amplification, and
one candidate oncogene, named chromodomain helicase DNA
binding protein 1-like gene (CHD1L, also called ALC1), was isolated
[9]. CHD1L belongs to the SNF2-like family, containing a conserved
SNF2_N domain, a helicase superfamily domain (HELICc) and a
Macro domain. In our previous study, we found that CHD1L has
strong oncogenic ability including increasing cellproliferation, colony
formation in soft agar, and tumor formation in nude mice, and
inhibiting tumor cell apoptosis [9]. To further investigate the in vivo
oncogenic role of CHD1L, CHD1L ubiquitous-expression transgenic
mouse model was generated and characterized in this study.
Spontaneous tumors were found in 10 transgenic mice over 22
months of period. In addition, ethanol intoxication was found to
promote the susceptibility of liver tumor formation in CHD1L-
transgenic mice. The molecular mechanism of CHD1L in HCC
development was also studied using mouse embryo fibroblasts (MEF).
Results
Generation of CHD1L transgenic mice
To further characterize the in vivo function of CHD1L, CHD1L
ubiquitous-expression transgenic mouse model was generated.
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6727CHD1L was cloned into plasmid pCAGGS (Fig. 1A) and
linearized constructs were injected into 773 F1 eggs and 40 pups
were obtained. Among them, 4 independent founders including 3
males (lines 3, 26 and 38) and 1 female (line 21), were identified by
PCR screening (Fig. 1B). Expression of CHD1L was confirmed
by Northern blot analysis using a human specific CHD1L probe
(Figure 1B). Two founders (lines 21 and 38) were capable of
transmitting the transgene to their offspring and thus chosen for
further functional studies (Table 1, Fig. 1D). Two different
BamHI fragments (6 kb in line 21 and 8 kb in line 38) containing
transgene CHD1L were detected by Southern blot analysis,
implying that CHD1L was integrated into different genomic sites
in lines 21 and 38 (Fig. 1D).
Characterization of CHD1L-transgenic mice
DNA sequence comparison showed that the homology
between human and mouse CHD1L is about 81.2%. The
endogenous expression of mouse CHD1L was studied by RT-
PCR using mouse-specific primers and the result showed that
high level expression of CHD1L was detected in brain, heart,
lung, kidney and stomach. Low expression of endogenous mouse
CHD1L was observed in liver and spleen (Fig. 2A). The
Figure 1. Generation of CHD1L-transgenic mouse model. (A) Construction of human CHD1L gene in pCAGGS for the generation of CHD1L-
transgenic mouse. (B) Four CHD1L-transgenic mouse (#3, 21, 26, and 38) founders were identified by PCR screening. Genomic DNA from cloned
CHD1L was used as positive controls. (C) CHD1L expression in transgenic mouse (#38) was confirmed by Northern blot analysis. (D) Two founders
(lines 21 and 38) were able to transmit the transgene to their offspring (P1). Genomic DNA was digested with BamHI and DNA fragment containing
transgene CHD1L was detected by Southern blot analysis. The size of BamHI-DNA fragment was 6 kb in line 21 and 8 kb in line 38, implying their
integrated sites in host genomic DNA are different .
doi:10.1371/journal.pone.0006727.g001
CHD1L-Transgenic Mice
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wildtype mice was tested by RT-CPR using human-specific
primers. The results showed that expression of CHD1L was
detected in all tested tissues (brain, heart, liver, lung, and
kidney) in transgenic mice but not in wildtype mice (Fig. 2B).
The expression of CHD1L in the liver of transgenic mice was
firstly detected at embryonic stage 13.5dpc (Fig. 2C). The
expression of CHD1L increased at 16dpc till 1 week after birth,
a n dt h e nd e c r e a s e ds l i g h t l ya t3t o2 0w e e k sp o s t n a t a l( Fig. 2C).
CHD1L-transgenic mice were indistinguishable from wild-type
siblings by size and weight.
Ethanol intoxication promotes liver tumor susceptibility
in transgenic mice
To investigate whether ethanol intoxication is able to promote
the susceptibility of liver tumor in CHD1L-transgenic mice, wild
type and CHD1L-transgenic mice (6 mice for each group) were
exposed to ethanol intoxication for a period of 12 weeks. Liver
Table 1. Summarization of CHD1L-transgenic founders and their offspring for tumorigenicity studies.
Founder Sex Offspring Tested Germline Transmission Rate Ethanol Intoxication
a Tumor Formation
b
#3 male 52 2 (2.8%)
#21 female 27 15 (55.6%) 27 (15)
#26 male 32 2 (6.25%)
#38 male 65 32 (49.23%) 12 (6) 53 (26)
aTotal number of offspring and CHD1L-transgenic offspring (in blanket) were used for ethanol intoxication study.
bTotal number of offspring and CHD1L-transgenic offspring (in blanket) were used for spontaneous tumor formation study.
doi:10.1371/journal.pone.0006727.t001
Figure 2. Characterization of CHD1L-transgenic mice. (A) Endogenous mouse CHD1L expression was tested by RT-PCR using mouse-specific
primers. Weak expression of CHD1L was detected in liver and spleen. GAPDH was used as internal control. (B) Expression of transgene CHD1L in
multiple tissues of transgenic and wildtype mice was studied by RT-PCR using human-specific primers in adult mice. GAPDH was used as internal
control. (C) Expression of CHD1L in liver at different ages was tested by RT-PCR. 18S rRNA was used as loading control.
doi:10.1371/journal.pone.0006727.g002
CHD1L-Transgenic Mice
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of the liver between the two groups of animals were compared. In
CHD1L-transgenic mice, a visible liver solid tumor and an
adipoma were observed in two different mice (Fig. 3A). Histology
study confirmed that the liver tumor was HCC (Fig. 3B). Severe
dysplasia lesion was observed in three other CHD1L-transgenic
mice (Fig. 3C). No visible tumor and dysplasia lesion was detected
in wildtype mice (Fig. 3D).
Following ethanol intoxication, the frequency of cell prolifera-
tion between CHD1L-transgenic and wildtype mice was compared
by PCNA staining. The result revealed that the cell proliferation
frequency was significantly higher in transgenic mice (5.5%) than
that of wildtype littermates (1.6%, p,0.05, Fig. 3E). In addition,
the expression of AFP can only be detected in CHD1L-transgenic
mice but not in their wildtype littermates (Fig. 3F). Taken
together, these observations suggest that overexpression of
CHD1L in hepatocytes promotes the susceptibility of tumor
formation in mouse.
Spontaneous tumor formation in CHD1L-transgenic mice
Only first-generation offspring from founder lines #21 and #38
(41 CHD1L-transgenic mice and 39 wildtype mice) were used as
study cohort. Spontaneous tumor formation was observed in 10/
41 (24.4%) transgenic mice, but not in their 39 wild-type
littermates over a monitoring period of 22 months. The places
of tumor formed and their pathological diagnosis were summa-
rized in Table 2. Liver tumors were observed in 4 mice and
histological study revealed that they were all HCC (Fig. 4). In
mouse 2, two liver tumors in similar size were found in different
lobes (Fig. 4B, indicated by arrows). Two other spontaneous
HCC tumors formed in CHD1L-transgenic mice were also shown
in Figure 4 (4C and 4D). In mouse 5, two spontaneous tumors
Figure 3. Ethanol intoxication promotes the susceptibility of liver tumor in CHD1L-transgenic mice. (A) A visible liver tumor (left) and
adipoma (right) were found in CHD1L-transgenic mice following the ethanol exposure. (B) Histological study confirms the liver tumor is HCC.
(C) Representative example of severe dysplasia lesion observed in a CHD1L- transgenic mouse following the ethanol exposure. (D) Representative
example of normal liver tissue observed in a wildtype mouse following the ethanol exposure. (E) PCNA staining results showed that the frequency of
cell proliferation (PCNA positive staining cells, indicated by arrows) was significantly higher in CHD1L-transgenic mice than that in wildtype
littermates. (F) Representative example of AFP positive staining detected in a CHD1L- transgenic mouse and AFP negative staining in a wildtype
mouse, respectively, after the ethanol exposure.
doi:10.1371/journal.pone.0006727.g003
CHD1L-Transgenic Mice
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Histological study revealed that they were salivary acinic cell
adenocarcinoma (Fig. 5A) and uterine adenofibroma, respective-
ly. In 10 CHD1L-transgenic mice suffered with tumor, different
tumor types were found including HCC, salivary acinic cell
adenocarcinoma, (Figs. 5A and 5B), rhabdomyosarcoma
(Fig. 5C), gall bladder adenocarcinoma, and colon adenocarci-
noma (Fig. 5D).
Overexpression of CHD1L promotes cell cycle in
transgenic MEF
Mouse embryonic fibroblasts (MEF) derived from CHD1L-
transgenic mice and their wildtype littermates were established
using embryos at 13.5dpc. Pool of two wildtype MEFs and two
CHD1L-transgenic MEFs were tested and their CHD1L expres-
sion level was determined by RT-PCR (Fig. 6A). DNA content
analysis with MEF cells by flow cytometry found that CHD1L
could facilitate DNA synthesis and G1/S transition (Fig. 6B). To
address the possible pathway involved, expressions of several cell
cycle-related genes, including Rb, Cyclin A, Cyclin D1, Cyclin E,
CDK2, CDK4, p27
kip1, and p53 were compared between
wildtype and CHD1L-transgenic MEFs. The results showed that
expressions of Cyclin A, Cyclin D1, CDK2, and CDK4 were
notably up-regulated and a slight increase in CyclinE expression
level, while Rb, p27
kip1 and p53 were down-regulated in CHD1L-
transgenic MEFs compared with wildtype MEFs (Fig. 6C).
Discussion
Amplification of 1q21 is one of the most frequently detected
genetic changes in HCC. Activation of oncogene plays critical role
in cancer development and one common mechanism of oncogene
activation is overexpression caused by DNA amplification. Our
previous study showed that amplification of 1q21 is an early event
in HCC development, implying that the putative oncogene within
this region may play important role in the initiation of HCC
pathogenesis [10]. Recently, one candidate oncogene, CHD1L,
was isolated from 1q21 and our previous study has demonstrated
its oncogenic ability. In this report, we described the generation
and characterization of a CHD1L-transgenic mouse model.
CHD1L transgenic mouse model established in this study
provides a very useful tool for investigating CHD1L function and
role in cancer development. Two founders (#21 and #38) were
capable of transmissing the transgene CHD1L to their offspring
and Southern blot analysis found that their integrating sites are
different. Therefore, these two lines were selected for further study.
Spontaneous tumor formation was found only in old CHD1L-
transgenic mice (over 20 months old), implying that the initiation
and progression of HCC carcinogenesis caused by abnormal
CHD1L expression is a long process. Several different types of
tumors were found in CHD1L-transgenic mice including HCC,
salivary, colon, uterine, and gall bladder adenocarcinoma, and
rhabdomyosarcoma. Amplification of 1q has been also frequently
detected in other solid tumors, including colon cancer [11], uterine
cancer [12], and rhabdomyosarcoma [13]. These data suggest that
CHD1L may play an important role in cancer development in
many solid tumors.
To shorten the latency of tumor onset, alcohol intoxication was
employed to induce hepatocyte pathological lesions. Alcohol is one
the major risk factor for hepatocellular carcinoma, especially in
western countries. Alcohol intoxication is a simple but efficient way
to induce liver lesions in cancer-prone marine [14]. Interestingly,
after 12 weeks alcohol treatment, 5/6 of CHD1L-transgenic mice
had liver lesions, including HCC, adipoma, and severe dysplasia.
However, no obvious precancerous lesion was detected in wildtype
controls. In addition, overexpression of CHD1L could increase
hepatocyte proliferation and induce AFP expression in transgenic
liver post alcohol treatment. These results suggest that overexpres-
sion of CHD1L in liver increases the tumor susceptibility.
Promotion of cell proliferation is a major molecular mechanism
of oncogene in cancer development. In this study, we demon-
strated that CHD1L could facilitate DNA synthesis and promoted
G1/S phase transition in CHD1L-transgenic MEFs. This result is
consistent with our previous finding, in which overexpression of
CHD1L in QGY-7703 (HCC cell line) cells could also promote
G1/S phase transition [9]. To further explore the molecular
mechanism of CHD1L in cell cycle promotion, expressions of
several G1/S phase transition checkpoint related proteins were
compared between CHD1L-transgenic and wildtype MEFs. The
results showed that CHD1L could up-regulate Cyclin A, Cyclin
D1, CDK2 and CDK4, and down-regulate Rb, p27
Kip1 and p53.
p27
Kip1 serves as a key mediator in G1/S transition through Cdk
inhibition and regulating the activity of cyclin D-Cdk4/6 complex
which are essential for S phase entry [15,16]. The reduced
expression of p27
Kip1 facilitates the activation of cyclin D-Cdk4/6
complex, resulting in the cyclin D-Cdk4/6-medicated Rb
phosphorylation and destruction of Rb-E2F binding. The
releasing E2F activates the transcription of genes necessary for S
phase entry and progression [17]. Overexpression of CHD1L
might serve as mitogenic signal to induce expression of cyclin D-
Cdk4/6 and inhibit the expression of p27
Kip1. In addition, the p53
protein is a transcription factor that upregulates the expression of
p21
Waf1/Cip1, which in turn functions as a Cdk2 inhibitor to
control S phase entry via the inactivation of cyclinE-Cdk2
complex. The notable upregulation of Cdk2 in CHD1L-transgenic
MEFs suggested that the dysregulation of the p53–cyclinE-Cdk2
pathway might be also involved in CHD1L-induced G1/S
transition. Taken together, the observations in the present study
strongly support that CHD1L is a novel oncogene responsible for
the 1q21 amplification event in HCC and plays an important role
in the development of HCC via promoting cell cycle.
Table 2. Summarization of spontaneous tumor formation in
CHD1L-transgenic mice.
Mouse
a Subcategory Organ Pathological Diagnosis
M1 (L21) tumor 1 liver HCC
tumor 2 abdomen wall adipoma
tumor 3 abdomen wall adipoma
M2 (L38) tumor 1 liver HCC
tumor 2 liver HCC
M3 (L38) tumor 1 liver HCC
M4 (L38) tumor 1 liver HCC
M5 (L21) tumor 1 neck salivary acinic cell adenocarcinoma
tumor 2 uterus uterine adenofibroma
M6 (L38) tumor 1 face salivary acinic cell adenocarcinoma
M7 (L38) tumor 1 gall bladder adenocarcinoma
M8 (L38) tumor 1 colon adenocarcinoma
M9 (L38) tumor 1 posterior limb rhabdomyosarcoma
M10 (L21) tumor 1 abdomen wall adipoma
aMouse number was listed as M1 to M10. Offspring from founder #21 or #38
was shown in blanket.
doi:10.1371/journal.pone.0006727.t002
CHD1L-Transgenic Mice
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Generation of CHD1L-transgenic mice
For construction of CHD1L-transgenic mice, a 2.8-kb EcoRI–
EcoRI fragment containing the open reading frame of human
CHD1L gene (Gene Bank accession no. AF537213), which was
amplified by PCR from normal human liver cell line LO-2
complementary DNA, was cloned into plasmid pCAGGS. Expres-
sionofCHD1LwasdrivenbyahumanCMV-IEenhancerlinked to
the chicken b-actin promoter, followed by its first exom and intron
(Fig. 1A). The human CHD1L has its own stop codon followed by a
rabbit b-globin poly(A) sequence. The mRNA transcript of the
transgene consists of the first exon of chicken b-actin, which is
transcribed but not translated, followed by the CHD1L transgene.
The generation of CHD1L-transgenic mice was performed using the
standard method [18]. Briefly, the linearized constructs were
injected into one-cell-stage F1 eggs (DBA6C57BL/6), which were
transplanted into pseudo-pregnant females (average 12 eggs per
oviduct).
All resulting pups were screened for the presence of the
transgene by PCR using genomic DNA obtained from tail snips
with a pair of human-specific primers (Forward: 59-AGC-
GCCTGGCTTCTTACTGC; Reverse: 59-GCTTATCCAG-
CAGGTGAAGCTTC). The CHD1L-transgenic founders were
crossed with wildtype F1 (DBA/C57bl6) and their first-generation
offsprings (47 CHD1L-transgenic mice and 45 wildtype mice) were
used as study cohort (Table 1). Mouse endogenous CHD1L
expression was tested by RT-PCR using a pair of mouse-specific
primers (Forward: 59-GGAGGAGGAAGCCTAGAACC; Re-
verse: 59-CGCTGCTTCCTGTCTTTTCT). Animal experimen-
tation was done according to the institutional guidelines
(Association for Assessment and Accreditation of Laboratory
Animal Care International) for animal care. All the animal
experiments were approved by the Committee on the Use of Live
Figure 4. Detection of spontaneous liver tumors in CHD1L-transgenic mice. (A) Representative example of a visible liver tumor in one
CHD1L-transgenic mouse (left), which was diagnosed as HCC by histological study (right). (B) Two liver tumors were found in one CHD1L-transgenic
mouse (left, indicated by arrows) and histological study confirmed they are HCCs. (C and D) Representative examples of other two HCCs observed in
CHD1L-transgenic mice.
doi:10.1371/journal.pone.0006727.g004
CHD1L-Transgenic Mice
PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6727Figure 5. Detection of spontaneous tumors in other organs in CHD1L-transgenic mice. Besides HCC, several other different tumors were
found in CHD1L-transgenic mice including salivary acinic cell adenocarcinoma (A and B), rhabdomyosarcoma (C), and colon adenocarcinoma (D).
doi:10.1371/journal.pone.0006727.g005
Figure 6. Overexpression of CHD1L promotes cell proliferation in CHD1L-transgenic MEF. (A) Detection of CHD1L expression in MEFs from
CHD1L-transgenic (Tg) and wild type (Wt) mice by RT-PCR. GAPDH was used as internal control. (B) Examples of DNA content in CHD1L-transgenic and
wild type MEFs detected by flow cytometry. (C) Western blot analyses indicated that Cyclin D1, Cyclin A and CDK2, 4 were up-regulated, whiles p53, Rb
and p27
Kip1 were down-regulated in CHD1L-transgenic MEFs compared with their wild type MEFs (pool of two MEFs). b-actin was used as loading control.
doi:10.1371/journal.pone.0006727.g006
CHD1L-Transgenic Mice
PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6727Animals in Teaching and Research (CULATR), The University of
Hong Kong.
Southern and Northern blot analyses
For Southern blot analysis, 10 mg of genomic DNA was digested
with BamHI, fractionated on 1% agarose gel, transferred to a nylon
membrane, and hybridized overnight at 42uC with
32P-labeled
probe for human CHD1L gene. For Northern blot analysis, 20 mg
of total cellular RNA was size fractionated, transferred to a nylon
membrane, and hybridized with
32P-labeled human CHD1L gene.
Ethanol intoxication
CHD1L-transgenic mice and their wild type littermates (6 mice
for each group) at age of 20-weeks old were fed ad libitum a mixture
containing increasing concentrations of ethanol (10% for 2 days;
15% for 3 days and thereafter 20%) in 20% sucrose during the
entire treatment period (12 weeks). This mixture was the only
source of drinking fluid for the animal for the entire duration of
the experiment. Animals were then kept without ethanol for 4
weeks before sacrificed.
Histological and pathological study
Animals with visible tumors were sacrificed when signs of
distress appeared. Tumors were immediately removed and fixed in
10% formalin for 24 hr. After dehydration, the tumor tissues were
paraffin embedded. Serial sections (5 mm in thickness) were
prepared, stained with Mayer’s hematoxylin-eosin (H&E), and
examined under microscope by two independent pathologists.
Immunohistochemistry (IHC) was performed using standard
streptavidin-biotin-peroxidase complex method with anti PCNA
and AFP (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies.
Generation of mouse embryo fibroblast (MEF)
Pregnant female mouse at 13.5 dpc was sacrificed and embryos
were collected. The embryos were minced thoroughly with sterile
scissors and then digested in 0.2% typsin (Sigma, St. Louis, MO) at
37uC for 10 min. The cell suspension was cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% FBS
at 37uC.
Detection of DNA content by flow cytometry
DNA content in CHD1L-transgenic MEF and wildtype MEF
was compared by flow cytometry. Cells were fixed in 70% ethanol
for at least 1 hr and stained with staining solution (100 mg/ml
RNase, 0.02% Triton X-100, 10 mg/ml propidium iodide) for
1 hr. Samples were analyzed using FACSCalibur flow cytometer
and CellQuest software (BD Biosciences, San Jose, CA).
Western blotting analysis
For Western blotting, 20 mg of protein extract was separated by
SDS–polyacrylamide gel electrophoresis and transferred to a
PVDF Hybond-P membrane (Amersham Pharmacia Biotechnol-
ogy, Piscataway, NJ). Western blot analyses were performed by a
standard method with antibodies to Rb, Cyclin D1, Cyclin A,
Cyclin E, CDK2, CDK4, p27
kip1, p53 and b-Actin (Cell Signaling
Technology, Beverley, MA).
Statistical analysis
The difference of PCNA positive cells in CHD1L-transgenic
liver and wildtype counterparts was compared with Student’s T-
test. The difference of DNA content between CHD1L-transgenic
and wildtype MEFs was compared with Student’s T-test. P values
of ,0.05 were considered to be significant.
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